Grufity logoGrufity logo
ScreenerStocksFundsSectorsWatchlists
AMED

Amedisys Inc

AMED

93.70USD-0.03 (-0.03%)Market Closed
Watchlist

Market Summary

USD93.70-0.03
Market Closed
-0.03%

AMED Stock Price

View Fullscreen

AMED RSI Chart

AMED Valuation

Market Cap

3.1B

Price/Earnings (Trailing)

1.2K

Price/Sales (Trailing)

1.37

EV/EBITDA

33.69

Price/Free Cashflow

27.25

AMED Price/Sales (Trailing)

AMED Profitability

EBT Margin

2.32%

Return on Equity

0.25%

Return on Assets

0.13%

Free Cashflow Yield

3.67%

AMED Fundamentals

AMED Revenue

Revenue (TTM)

2.2B

Revenue Y/Y

-0.31%

Revenue Q/Q

0.59%

AMED Earnings

Earnings (TTM)

2.6M

Earnings Y/Y

1.24%

Earnings Q/Q

132.34%

Price Action

Last 7 days

0.7%

Last 30 days

0.8%

Last 90 days

0.4%

Trailing 12 Months

7.6%

How does AMED drawdown profile look like?

AMED Financial Health

Current Ratio

1

Debt/Equity

0.35

Debt/Cashflow

0.32

AMED Investor Care

Shares Dilution (1Y)

0.47%

Diluted EPS (TTM)

0.07

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20232.2B2.2B2.2B0
20222.2B2.2B2.2B2.2B
20212.1B2.2B2.2B2.2B
20202.0B2.0B2.0B2.1B
20191.7B1.8B1.9B2.0B
20181.5B1.6B1.6B1.7B
20171.5B1.5B1.5B1.5B
20161.3B1.4B1.4B1.4B
20151.2B1.2B1.2B1.3B
20141.2B1.2B1.2B1.2B
20131.4B1.4B1.3B1.2B
20121.5B1.5B1.5B1.4B
20111.6B1.5B1.5B1.5B
20101.5B1.6B1.6B1.6B
20091.3B1.4B1.4B1.5B
2008820.3M942.7M1.1B1.2B
2007000697.9M

Latest Insider Trading transactions for AMED

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Oct 20, 2023
holton adam y
sold (taxes)
-47,204
92.74
-509
chief people officer
Jul 25, 2023
muscato nick
sold (taxes)
-15,473
91.02
-170
chief strategy officer
Jun 26, 2023
ginn scott g
acquired
-
-
16,446
evp, cfo & acting coo
Jun 26, 2023
ashworth richard m
acquired
-
-
27,410
president and ceo
Jun 10, 2023
bohnert denise m.
sold (taxes)
-42,870
91.8
-467
chief compliance officer
May 03, 2023
rideout jeffrey a
acquired
-
-
1,941
-
May 03, 2023
coye molly joel
acquired
-
-
1,941
-
May 03, 2023
kline teresa l.
acquired
-
-
1,941
-
May 03, 2023
klapstein julie d
acquired
-
-
1,941
-
May 03, 2023
perkins bruce d
acquired
-
-
1,941
-

1–10 of 50

Which funds bought or sold AMED recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Dec 07, 2023
Hudson Bay Capital Management LP
added
1,952
29,611,200
31,094,000
0.12%
Dec 06, 2023
CITIGROUP INC
added
0.74
476,212
16,915,000
0.01%
Dec 06, 2023
Raleigh Capital Management Inc.
unchanged
-
59.00
2,802
-%
Nov 29, 2023
Carmignac Gestion
added
373
2,498,220
3,149,920
0.06%
Nov 27, 2023
BANQUE PICTET & CIE SA
unchanged
-
18,404
877,026
0.01%
Nov 24, 2023
DEUTSCHE BANK AG\
reduced
-95.52
-3,206,690
153,643
-%
Nov 21, 2023
COMERICA BANK
reduced
-22.49
1,274,950
1,275,950
0.01%
Nov 16, 2023
Financial Gravity Asset Management, Inc.
reduced
-98.9
-47.00
113
-%
Nov 16, 2023
Creative Planning
reduced
-2.08
56.00
325,098
-%
Nov 15, 2023
Baker Avenue Asset Management, LP
added
86.36
1,817
3,829
-%

1–10 of 42

Latest Funds Activity

Are funds buying AMED calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own AMED
No. of Funds

Schedule 13G FIlings of Amedisys Inc

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jul 06, 2023
jpmorgan chase & co
2.3%
774,361
SC 13G/A
May 18, 2023
flynn james e
5.51%
1,794,000
SC 13G
Feb 14, 2023
ameriprise financial inc
3.39%
1,100,719
SC 13G/A
Feb 09, 2023
vanguard group inc
9.63%
3,128,416
SC 13G/A
Feb 06, 2023
wellington management group llp
8.63%
2,802,831
SC 13G/A
Jan 26, 2023
blackrock inc.
12.6%
4,106,566
SC 13G/A
Jan 20, 2023
blackrock inc.
12.6%
4,106,566
SC 13G
Jan 06, 2023
jpmorgan chase & co
5.4%
1,763,327
SC 13G
Feb 14, 2022
ameriprise financial inc
5.35%
1,742,916
SC 13G
Feb 09, 2022
vanguard group inc
9.69%
3,158,777
SC 13G/A

Recent SEC filings of Amedisys Inc

View All Filings
Date Filed Form Type Document
Oct 25, 2023
10-Q
Quarterly Report
Oct 24, 2023
8-K
Current Report
Oct 24, 2023
4
Insider Trading
Sep 08, 2023
8-K
Current Report
Sep 05, 2023
3
Insider Trading
Sep 01, 2023
DEFA14A
DEFA14A
Sep 01, 2023
8-K
Current Report

AMED Fair Value

Loading...

Peers (Alternatives to Amedisys Inc)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
508.7B
360.0B
2.46% 0.72%
23.46
1.41
14.24% 11.62%
96.7B
347.8B
9.25% -26.74%
11.1
0.28
10.34% 159.11%
91.1B
189.9B
-12.37% -22.06%
13.64
1.92
5.24% 22.27%
69.2B
63.2B
11.16% 6.57%
12.11
1.1
5.62% 6.32%
39.4B
150.1B
4.91% -14.72%
16.13
0.26
6.04% 21.35%
MID-CAP
9.8B
11.9B
26.82% 43.59%
16.13
0.82
2.36% -10.41%
9.6B
14.0B
6.07% 6.08%
14.25
0.69
6.03% -8.61%
8.6B
2.2B
-1.60% 9.83%
35.34
3.88
4.50% -6.69%
6.7B
2.9B
-0.53% -12.01%
-365.93
2.34
13.16% -106.47%
2.6B
4.1B
13.56% -40.93%
9.25
0.63
-25.26% -41.25%
SMALL-CAP
1.6B
1.3B
4.12% 12.39%
34.86
1.17
27.06% -27.04%
1.5B
1.0B
10.48% -13.37%
25.78
1.44
10.84% 30.19%
1.0B
3.0B
22.30% 77.33%
-8.11
0.34
6.98% 58.07%
35.8M
-
8.80% -76.75%
-2.47
-
- -27.68%
15.8M
20.7M
12.00% -11.27%
54.39
0.76
6.53% -78.75%

Amedisys Inc News

Latest updates
MarketBeat05 Dec 202305:47 pm4 days ago
Yahoo Finance29 Nov 202308:00 am10 days ago
Defense World26 Nov 202310:48 am13 days ago
Seeking Alpha03 Nov 202307:00 am36 days ago
Yahoo Finance24 Oct 202307:00 am46 days ago
Yahoo Finance24 Oct 202307:00 am46 days ago
Marketscreener.com18 Oct 202307:00 am52 days ago
Seeking Alpha04 Oct 202307:00 am2 months ago
Nasdaq02 Oct 202307:00 am2 months ago
Nasdaq27 Sep 202307:00 am2 months ago
Hospice News05 Sep 202307:00 am3 months ago
Home Health Care News23 Aug 202307:00 am3 months ago
Seeking Alpha31 Jul 202307:00 am4 months ago
JD Supra28 Jul 202307:00 am4 months ago
Home Health Care News27 Jul 202307:00 am4 months ago

Financials for Amedisys Inc

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue0.6%556553556562558558545559554564537551544485492501495493467434417
Costs and Expenses-0.2%514515514516519510497511497491477495486458448459448448423398377
EBITDA Margin5.5%0.04*0.04*0.09*0.09*0.10*0.11*0.13*0.14*0.15*0.16*0.13*0.12*0.11*0.10*0.10*------
Interest Expenses6.9%8.008.008.006.005.008.003.003.003.002.002.002.003.003.003.003.004.004.003.002.002.00
Income Taxes-32.4%12.0018.0010.0010.009.0011.0012.0013.0011.0029.0018.0016.00-10.2010.009.0011.0010.0010.0011.009.0010.00
Earnings Before Taxes161.0%38.00-62.2335.0041.0035.0040.0044.0047.0056.0010968.0062.0062.0045.0041.0039.0044.0044.0042.0037.0041.00
EBT Margin6.5%0.02*0.02*0.07*0.07*0.07*0.08*0.12*0.13*0.13*0.14*0.11*0.10*0.09*0.09*0.09*------
Net Income132.3%26.00-80.2825.0032.0026.0030.0032.0034.0045.0080.0050.0045.0072.0035.0032.0028.0034.0034.0031.0028.0031.00
Net Income Margin13.8%0.00*0.00*0.05*0.05*0.05*0.06*0.09*0.09*0.10*0.11*0.10*0.09*0.08*0.07*0.06*------
Free Cashflow-118.2%-10.8359.0025.0039.00-15.1956.0048.004.0060.0067.0052.0064.0082.001345.00------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets2.3%2,0271,9821,9471,9761,9822,0011,9081,8571,9381,6001,5731,5671,6031,6451,4401,2631,2121,2061,184717726
  Current Assets9.5%467427406389389395392357433391380362411450468351300276272224233
    Cash Equivalents-18.1%78.0095.0049.0041.0031.0049.0071.0046.0012893.0078.0083.0011518017896.0021.0014.0011.0020.0014.00
  Net PPE8.9%40.0036.0033.0016.0017.0018.0017.0018.0020.0021.0022.0024.0024.0025.0026.0028.0030.0030.0030.0029.0030.00
  Goodwill0%1,2451,2451,2451,2871,2851,2909.001,1961,188937933933931937721659660665650330324
Liabilities1.3%934922814870913962888881989724784756845923760621609643663234280
  Current Liabilities1.2%468462353356367427380374454449456456437442316327315313297222219
  Long Term Debt-0.8%3673703734194434424294324351792312053013933802322322663046.0055.00
    LT Debt, Current------------11.00---10.00---2.00-
    LT Debt, Non Current------------205---232---6.00-
Shareholder's Equity-2.0%1,0401,0611,1331,0521,0701,0391,021976949876790811758722680642603563521483445
  Retained Earnings3.7%72970378375872670067163960556048043038531327824621918515112092.00
  Additional Paid-In Capital1.1%777769759755751743737728721714707698690666656645635623614604593
Accumulated Depreciation3.7%94.0091.0010510110210099.0097.0010099.0098.0095.0010210198.0096.0010199.0097.0095.0093.00
Shares Outstanding0.1%33.0033.0033.0033.0032.0033.0033.0033.0033.0033.0033.0033.0033.0032.0032.0032.0032.0032.0032.0032.0032.00
Minority Interest-0.7%54.0054.0054.0055.0054.0053.0054.0045.0044.002.001.002.002.001.001.001.001.001.001.001.001.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations-116.2%-9,843,00060,759,00025,961,00040,883,000-13,630,00057,409,00048,621,0005,166,00061,767,00067,958,00054,002,00065,912,00083,083,000133,922,0006,035,00075,220,00047,455,00059,266,00020,059,00064,033,00068,480,000
  Share Based Compensation-20.5%7,243,0009,108,0003,273,000570,0003,495,0005,148,0007,347,0005,940,0004,397,0006,156,0007,307,0006,972,0007,124,0006,725,0005,909,0006,589,0006,298,0005,538,0006,615,0005,247,0004,842,000
Cashflow From Investing86.5%-1,048,000-7,745,00045,896,000-1,866,000-1,033,000-75,508,000-16,079,000-11,667,000-264,561,000-3,822,000-1,557,000-1,565,000-1,221,000-213,567,000-70,755,000-1,386,000-3,604,000-19,046,000-328,912,000-9,572,000-7,418,000
Cashflow From Financing42.9%-6,254,000-10,953,000-56,890,000-16,344,000-2,641,000-4,046,000-7,402,000-75,938,000238,356,000-49,834,000-57,458,000-96,443,000-146,736,00082,160,000146,042,0001,899,000-36,996,000-36,872,000299,178,000-48,242,000-72,956,000
  Buy Backs------17,351,000-14,999,00010,805,0001,188,00072,886,000----------

AMED Income Statement

2023-09-30
CONSOLIDATED INCOME STATEMENT - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Income Statement [Abstract]    
Net service revenue$ 556,237$ 557,988$ 1,665,594$ 1,661,135
Cost of service, inclusive of depreciation311,628322,227924,093943,258
General and administrative expenses:    
Salaries and benefits129,083125,550380,926376,788
Non-cash compensation6,6123,49518,96815,990
Merger-related expenses4,980025,1510
Depreciation and amortization4,4365,47713,60419,705
Investment impairment03,00903,009
Other57,28759,299180,467167,851
Total operating expenses514,026519,0571,543,2091,526,601
Operating income42,21138,931122,385134,534
Other income (expense):    
Interest income1,304592,452108
Interest expense(8,021)(4,963)(23,040)(16,447)
Equity in earnings (loss) from equity method investments1,2523029,366(442)
Merger termination fee00(106,000)0
Miscellaneous, net1,2014915,2621,155
Total other expense, net(4,264)(4,111)(111,960)(15,626)
Income before income taxes37,94734,82010,425118,908
Income tax expense(12,331)(9,417)(40,381)(32,755)
Net income (loss)25,61625,403(29,956)86,153
Net loss attributable to noncontrolling interests344239887739
Net income (loss) attributable to Amedisys, Inc.$ 25,960$ 25,642$ (29,069)$ 86,892
Basic earnings per common share:    
Net income (loss) attributable to Amedisys, Inc. common stockholders$ 0.80$ 0.79$ (0.89)$ 2.67
Weighted average shares outstanding, basic (shares)32,62432,48232,58732,519
Diluted earnings per common share:    
Net income (loss) attributable to Amedisys, Inc. common stockholders$ 0.79$ 0.79$ (0.89)$ 2.66
Weighted average shares outstanding, diluted (shares)32,83132,61632,58732,680

AMED Balance Sheet

2023-09-30
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 78,112$ 40,540
Restricted cash15,90413,593
Patient accounts receivable319,580296,785
Prepaid expenses20,53411,628
Other current assets33,09726,415
Total current assets467,227388,961
Property and equipment, net of accumulated depreciation of $93,909 and $101,36439,63116,026
Operating lease right of use assets87,834102,856
Goodwill1,244,6791,287,399
Intangible assets, net of accumulated amortization of $12,838 and $14,604103,634101,167
Other assets84,41279,836
Total assets2,027,4171,976,245
Current liabilities:  
Accounts payable34,55543,735
Payroll and employee benefits126,989125,387
Accrued expenses139,100137,390
Termination fee paid by UnitedHealth Group106,0000
Current portion of long-term obligations35,36415,496
Current portion of operating lease liabilities26,11133,521
Total current liabilities468,119355,529
Long-term obligations, less current portion366,853419,420
Operating lease liabilities, less current portion61,87869,504
Deferred income tax liabilities35,39820,411
Other long-term obligations1,6514,808
Total liabilities933,899869,672
Commitments and Contingencies—Note 6 
Equity:  
Preferred stock, $0.001 par value, 5,000,000 shares authorized; none issued or outstanding00
Common stock, $0.001 par value, 60,000,000 shares authorized; 38,065,853 and 37,891,186 shares issued; 32,633,599 and 32,511,465 shares outstanding3838
Additional paid-in capital776,880755,063
Treasury stock, at cost, 5,432,254 and 5,379,721 shares of common stock(465,613)(461,200)
Retained earnings728,603757,672
Total Amedisys, Inc. stockholders’ equity1,039,9081,051,573
Noncontrolling interests53,61055,000
Total equity1,093,5181,106,573
Total liabilities and equity$ 2,027,417$ 1,976,245
AMED
Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through four segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including cancer, heart disease, pulmonary disease, or Alzheimer's. The Personal Care segment provides assistance for patients with the activities of daily living. The High Acuity Care offers essential elements of inpatient hospital, skilled nursing facility care, and palliative care to patients in their homes. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana.
 CEO
 WEBSITEwww.amedisys.com
 EMPLOYEES20000

Amedisys Inc Frequently Asked Questions


What is the ticker symbol for Amedisys Inc? What does AMED stand for in stocks?

AMED is the stock ticker symbol of Amedisys Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Amedisys Inc (AMED)?

As of Fri Dec 08 2023, market cap of Amedisys Inc is 3.06 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AMED stock?

You can check AMED's fair value in chart. The fair value of Amedisys Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Amedisys Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AMED so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Amedisys Inc a good stock to buy?

The fair value guage provides a quick view whether AMED is over valued or under valued. Whether Amedisys Inc is cheap or expensive depends on the assumptions which impact Amedisys Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AMED.

What is Amedisys Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 08 2023, AMED's PE ratio (Price to Earnings) is 1.15 Thousand and Price to Sales (PS) ratio is 1.37. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AMED PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Amedisys Inc's stock?

In the past 10 years, Amedisys Inc has provided 0.197 (multiply by 100 for percentage) rate of return.